Answers are grounded in this paper and cite their sources.
The limited ability of enzyme replacement therapy (ERT) in removing globotriaosylceramide from cardiomyocytes is recognized for advanced Fabry disease cardiomyopathy (FDCM). Prehypertrophic FDCM is believed to be cured or stabilized by ERT. However, no pathologic confirmation is available. We report here on the long-term clinical-pathologic impact of ERT on prehypertrophic FDCM.
No takes yet. Share an insight, caveat, or question.
Frustaci et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: